The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...

As of Monday, the Nasdaq Composite index had tumbled more than 11% since the start of the year. The outlook for the economy ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

Osteoporosis drug Prolia faces intense competition as patents expire and generics launch Intense rivalry emerges in the osteoporosis treatment market as patent expirations lead to a surge of generic ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

In addition, Fresenius’ operating company has reached a global settlement with Amgen concerning its denosumab biosimilars. “We are pleased to have reached a global settlement with Amgen for ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ ...

On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...

Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...

The FDA accepted Fresenius’s BLA for its denosumab biosimilar on May 27, 2024. On October 4, 2024, Amgen filed its Complaint against Fresenius in the District Court for the Northern District of ...